-

Gilead's Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF

LOS ANGELES--(BUSINESS WIRE)--While Gilead is raking in blowout profits, many state AIDS Drug Assistance Programs (ADAPs) can no longer afford the high prices of its HIV medications. State support programs are scrambling to contain costs as financial analysts await the company’s earnings call for the first quarter of 2026 (Earnings Call, Thursday, May 7th). Low-income patients that rely on state assistance will not share the good news expected by investors.

Last year, HIV product sales were the driving force behind Gilead’s revenue, accounting for 72% of total sales. In 2025, Biktarvy, Gilead’s premier HIV medication regimen, cost $61,000 for a year of treatment.

Share

Last year, HIV product sales were the driving force behind the company’s revenue, accounting for 72% of total sales. Sales of treatments for people living with HIV were up 6% from 2024, totaling $20.8 billion. Biktarvy sales saw a 7% jump from the prior year, generating $14.3 billion in revenue. In 2025, Gilead’s premier HIV medication regimen cost $61,000 for a year of treatment. The prohibitive cost is making the treatment preferred by the majority of patients and their medical prescribers unaffordable for state assistance programs.

Florida is the first state to completely remove Biktarvy from its drug formulary, but likely will not be the last. In fact, 19 states are projecting budget deficits for the upcoming fiscal year. Cost containment measures are the new norm; fiscal reality means states will cover older, less effective drugs for the patients most in need.

Analysts expect a hefty 52% year-over-year earnings per share jump for Gilead in the first quarter of 2026. The prediction is little solace to the low-income patients receiving drugs from lifeline support programs.

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.9 million individuals across 50 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center’s highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

Contacts

Ged Kenslea, Senior Director, AHF Communications
(323) 791-5526 c ged.kenslea@ahf.org

John Hassell, AHF National Director of Advocacy
(202) 774-4854 c john.hassell@ahf.org

AIDS Healthcare Foundation


Release Summary
Gilead's Earnings per Share Expected to Be Up 52% as Florida’s and other States’ AIDS Drug Programs Falters, says AHF
Release Versions
Hashtags

Contacts

Ged Kenslea, Senior Director, AHF Communications
(323) 791-5526 c ged.kenslea@ahf.org

John Hassell, AHF National Director of Advocacy
(202) 774-4854 c john.hassell@ahf.org

Social Media Profiles
More News From AIDS Healthcare Foundation

Club de Madrid and AHF Global Public Health Institute Co-Host High-Level Roundtable on Rebalancing Global Health

NEW YORK--(BUSINESS WIRE)--The AIDS Healthcare Foundation (AHF) Global Public Health Institute, Club de Madrid and partners will join the Governments of Spain and Zambia in co-hosting a high-level roundtable, “Rebalancing Global Health: Regional Platforms, Equity, and Fiscal Space for Public Health Security,” on Thursday, Sept. 24, 2026, from 8:30 to 10:30 a.m. at the University Club in New York City and online via Zoom. The event will occur on the margins of the 81st United Nations General Ass...

Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), the world’s largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society. AHF was among the first organizations to mobilize around concerns that the initial Gilead-...

AHF to Commemorate 40 Years of Global Impact During Annual World AIDS Day Concert Celebration

LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), the world’s largest, non-profit public health organization providing direct HIV/AIDS services to over 3.3 million clients across the globe, will celebrate 40 years of impact during its annual World AIDS Day concert commemoration. The event, which is free and open to the public, is scheduled for the evening of Monday, November 30, 2026, at the Kia Forum in Inglewood, California. RSVP to AHFWAD.org for tickets. Commemorated annually...
Back to Newsroom